STOCK TITAN
  1. Home
  2. Sec-filings
  3. PPBT
  4. [6-K] Purple Biotech Ltd. American Current Report (Foreign Issuer)

[6-K] Purple Biotech Ltd. American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock PPBT logo
Purple Biotech Ltd

NASDAQ:PPBT

PPBT Rankings

#9967 Ranked by Market Cap
N/A Ranked by Dividends

PPBT Latest News

Jul 23, 2025
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
Jun 23, 2025
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Jun 17, 2025
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
Jun 4, 2025
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
May 21, 2025
Purple Biotech Reports First Quarter 2025 Financial Results

PPBT Latest SEC Filings

Jul 10, 2025
[6-K] Purple Biotech Ltd. American Current Report (Foreign Issuer)
Jun 23, 2025
[6-K] Purple Biotech Ltd. American Current Report (Foreign Issuer)

PPBT Stock Data

7.23M
2.60M
1.99%
3.04%
1.83%
Biotechnology
Healthcare
Link
Israel
Rehovot